Overall survival with circulating tumor DNA-guided therapy in advanced non-small-cell lung cancer-Reference-Cited by-同舟云学术

Overall survival with circulating tumor DNA-guided therapy in advanced non-small-cell lung cancer

Published:2022-11 Issue:11 Volume:28 Page:2353-2363
ISSN:1078-8956
Container-title:Nature Medicine
language:en
Short-container-title:Nat Med

Author:

Jee Justin^ORCID,Lebow Emily S.,Yeh Randy^ORCID,Das Jeeban P.,Namakydoust Azadeh,Paik Paul K.,Chaft Jamie E.^ORCID,Jayakumaran Gowtham,Rose Brannon A.^ORCID,Benayed Ryma^ORCID,Zehir Ahmet^ORCID,Donoghue Mark,Schultz Nikolaus^ORCID,Chakravarty Debyani^ORCID,Kundra Ritika^ORCID,Madupuri Ramyasree,Murciano-Goroff Yonina R.,Tu Hai-Yan,Xu Chong-Rui^ORCID,Martinez Andrés,Wilhelm Clare,Galle Jesse,Daly Bobby,Yu Helena A.^ORCID,Offin Michael^ORCID,Hellmann Matthew D.,Lito Piro^ORCID,Arbour Kathryn C.^ORCID,Zauderer Marjorie G.^ORCID,Kris Mark G.,Ng Kenneth K.,Eng Juliana,Preeshagul Isabel,Victoria Lai W.,Fiore John J.,Iqbal Afsheen,Molena Daniela^ORCID,Rocco Gaetano,Park Bernard J.,Lim Lee P.,Li Mark,Tong-Li Candace^ORCID,De Silva Madhawa,Chan David L.,Diakos Connie I.,Itchins Malinda,Clarke Stephen^ORCID,Pavlakis Nick,Lee Adrian,Rekhtman Natasha,Chang Jason,Travis William D.,Riely Gregory J.,Solit David B.^ORCID,Gonen Mithat,Rusch Valerie W.,Rimner Andreas^ORCID,Gomez Daniel,Drilon Alexander^ORCID,Scher Howard I.,Shah Sohrab P.^ORCID,Berger Michael F.^ORCID,Arcila Maria E.,Ladanyi Marc,Levine Ross L.^ORCID,Shen Ronglai^ORCID,Razavi Pedram^ORCID,Reis-Filho Jorge S.^ORCID,Jones David R.^ORCID,Rudin Charles M.^ORCID,Isbell James M.^ORCID,Li Bob T.^ORCID

Publisher

Springer Science and Business Media LLC

Subject

General Biochemistry, Genetics and Molecular Biology,General Medicine

Link

https://www.nature.com/articles/s41591-022-02047-z.pdf

Reference76 articles.

1. Kris, M. G. et al. Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. JAMA 311, 1998–2006 (2014).

2. Howlader, N. et al. The effect of advances in lung-cancer treatment on population mortality. N. Engl. J. Med. 383, 640–649 (2020).

3. Pasche, B. & Grant, S. C. Non-small cell lung cancer and precision medicine a model for the incorporation of genomic features into clinical trial design. JAMA 311, 1975 (2014).

4. Bruno, D. S. et al. Racial disparities in biomarker testing and clinical trial enrollment in non-small cell lung cancer (NSCLC). J. Clin. Oncol. 39, 9005 (2021).

5. Robert, N. J. et al. Biomarker tissue journey among patients (pts) with untreated metastatic non-small cell lung cancer (mNSCLC) in the U.S. Oncology Network community practices. J. Clin. Oncol. 39, 9004 (2021).

Cited by 68 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Optimal systemic treatment and real-world clinical application of ctDNA in patients with metastatic HER2-mutant lung cancer;European Journal of Cancer;2024-10

2. A Real-World Assessment of Stage I Lung Cancer Through Electronic Nose Technology;Journal of Thoracic Oncology;2024-09

3. The Study of PIK3CA Hotspot Mutations and Co-Occurring with EGFR, KRAS, and TP53 Mutations in Non-Small Cell Lung Cancer;OncoTargets and Therapy;2024-09

4. Circulating tumor DNA-based stratification strategy for chemotherapy plus PD-1 inhibitor in advanced non-small-cell lung cancer;Cancer Cell;2024-09

5. Medullary thyroid cancer: single-cell transcriptome and tumor evolution;Holistic Integrative Oncology;2024-08-30